{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:46:42Z","timestamp":1792057602271,"version":"4.4.0"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) is an effective treatment for HIV\u20101 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking. The primary 24\u2010week and secondary 48\u2010week analyses of study GS\u2010US\u2010380\u20104449 (NCT03405935), which assessed the efficacy and safety of switching to B\/F\/TAF in older PLWH, have been published. Here we report the results of the final 96\u2010week analyses from the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this 96\u2010week, phase 3b, open\u2010label, single\u2010arm trial, virologically suppressed PLWH aged \u226565\u2009years switched from elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide or a tenofovir disoproxil fumarate\u2010based regimen to B\/F\/TAF. Viral suppression, resistance, immune response, safety, tolerability and adherence were evaluated through week 96.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 90 participants screened, 86 were enrolled and switched to B\/F\/TAF. No participants had HIV\u20101 RNA \u226550 copies\/ml (by FDA Snapshot algorithm) at weeks 72 or 96; virologic suppression rates were 94.2% (81\/86; 95% CI 87.0\u201398.1) and 74.4% (64\/86; 95% CI 63.9\u201383.2), respectively. No treatment\u2010emergent resistance was observed, and CD4 counts remained stable. There were no study drug\u2010related serious adverse events. Three participants experienced drug\u2010related treatment\u2010emergent adverse events that led to premature drug discontinuation. There were no clinically relevant changes from baseline to week 96 in fasting lipid parameters, and the median change in body weight at week 96 was 0.0\u00a0kg (IQR \u22122.3, 2.0). Median self\u2010reported adherence was 100% (IQR 100\u2013100%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Switching to B\/F\/TAF is an effective long\u2010term option for virologically suppressed adults \u226565\u2009years of age, with favourable safety and tolerability profiles in this population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13319","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T05:45:34Z","timestamp":1652075134000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with <scp>HIV<\/scp>: Results of a 96\u2010week, phase 3b, open\u2010label, switch trial in virologically suppressed people \u226565\u2009years of age"],"prefix":"10.1111","volume":"24","author":[{"given":"Franco","family":"Maggiolo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases ASST Papa Giovanni XXIII  Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Luigi Sacco Hospital, ASST Fatebenefratelli Sacco  Milan Italy"},{"name":"School of Clinical Medicine, Faculty of Health Science University of the Witwatersrand  Johannesburg South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Saint Louis Hospital University Paris Diderot  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[{"name":"Unidad VIH Hospital Universitario 12 de Octubre, imas12, UCM  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"De Wit","sequence":"additional","affiliation":[{"name":"St Pierre University Hospital Universit\u00e9 Libre de Bruxelles  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[{"name":"University Hospital Ghent  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[{"name":"Infectious Diseases Hospital General Universitario Gregorio Mara\u00f1\u00f3n (IiSGM)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"D'Antoni","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Blair","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Chuck","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Piontkowsky","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haubrich","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"McNicholl","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-1642","authenticated-orcid":false,"given":"Joel","family":"Gallant","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,8]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Centers for Disease Control and Prevention.HIV and older Americans [Internet].2020. Accessed November 22 2021.https:\/\/www.cdc.gov\/hiv\/group\/age\/olderamericans\/index.html"},{"key":"e_1_2_9_3_1","unstructured":"KasaieP StewartC HumesE Gerace L Gebo K Boyd C et al.Multimorbidity in people with HIV using ART in the US: projections to 2030. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 6\u201310 2021; Virtual. Oral 102.https:\/\/www.croiconference.org\/abstract\/multimorbidity-in-people-with-hiv-using-art-in-the-us-projections-to-2030\/"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001335"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001967"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2018.0190"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2043"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz531"},{"key":"e_1_2_9_9_1","unstructured":"Department of Health and Human Services.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV [Internet].2021. Accessed November 22 2021.https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/archive\/AdultandAdolescentGL_2021_08_16.pdf"},{"key":"e_1_2_9_10_1","unstructured":"European AIDS Clinical Society.Guidelines. Version 10.1 [Internet].2020.https:\/\/www.eacsociety.org\/files\/guidelines-10.1_finaljan2021_1.pdf"},{"key":"e_1_2_9_11_1","unstructured":"Gilead Sciences.Biktarvy 50 mg\/200 mg\/25 mg film\u2010coated tablets: European summary of product characteristics [Internet].2018. Accessed July 5 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/biktarvy\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_12_1","unstructured":"Gilead Sciences.BIKTARVY\u00ae (bictegravir emtricitabine and tenofovir alafenamide) tablets for oral use: US prescribing information [Internet].2018. Accessed November 22 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210251Orig1s000lbl.pdf"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001306"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0203"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002137"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00419-5"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30080-3"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa625"},{"key":"e_1_2_9_24_1","unstructured":"US Food and Drug Administration.Human immunodeficiency virus\u20101 infection: developing antiretroviral drugs for treatment. [Internet].2015. Accessed November 22 2021.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/human\u2010immunodeficiency\u2010virus\u20101\u2010infection\u2010developing\u2010antiretroviral\u2010drugs\u2010treatment."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1198"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203895"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002266"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-016-9827-3"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002454"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz347"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002655"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002853"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab444"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13319","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:24:55Z","timestamp":1694431495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/hiv.13319"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13319","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,8]]},"assertion":[{"value":"2022-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}